Fulvestrant

Fulvestrant is a selective estrogen receptor degrader (SERD) used in the treatment of hormone receptor-positive (HR+) metastatic breast cancer in postmenopausal women. It binds to and degrades the estrogen receptor, blocking estrogen-driven tumor growth.

Mediocon Inc supplies Fulvestrant IP/BP/EP/USP as a high-purity oncology active pharmaceutical ingredient for licensed parenteral formulation manufacturers. With extensive GMP quality controls and multi-pharmacopoeial compliance, our Fulvestrant supports global regulatory submissions.

Key Features

• Selective estrogen receptor degrader (SERD)
• No partial agonist activity
• Multi-pharmacopoeial compliance (IP/BP/EP/USP)
• Compatible with injectable formulations

Applications

• HR+ metastatic breast cancer formulations
• Parenteral oncology injectables
• Endocrine therapy pharmaceutical manufacturing
• Oncology clinical research supply

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings